Efficacy, immunogenicity and safety of the AS04 ‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial

ConclusionsThis is the first large ‐scale randomized clinical trial of HPV vaccination in China. High and sustained vaccine efficacy against HPV‐16/18‐associated infection and cervical lesions was demonstrated up to Month 72. The vaccine had an acceptable safety profile. Combined with screening, prophylactic HPV vaccination cou ld potentially reduce the high burden of HPV infection and cervical cancer in China.Trial registrationNCT00779766.

Source: Cancer Medicine - July 14, 2019 Category: Cancer & Oncology Authors: Feng ‐Cai Zhu, Shang‐Ying Hu, Ying Hong, Yue‐Mei Hu, Xun Zhang, Yi‐Ju Zhang, Qin‐Jing Pan, Wen‐Hua Zhang, Fang‐Hui Zhao, Cheng‐Fu Zhang, Xiaoping Yang, Jia‐Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang Tags: ORIGINAL RESEARCH Source Type: research